Roche Holding AG

Roche Holding AG is a research healthcare company. It operates through the Roche Pharmaceuticals and Diagnostics segments. The Roche Pharmaceutical division comprises the business segments, such as Roche Pharmaceuticals and Chuga. The Diagnostic division consists of the following four business areas: centralized and point of care solutions, molecular diagnostics, tissue diagnostics and diabetes care. The company was founded by Fritz Hoffmann-La Roche on October 1, 1896 and is headquartered in Basel, Switzerland.

Basel, 12 March 2024 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that its shareholders had approved all proposals of the Board of Directors at its Annual General Meeting. The 635 shareholders in attendance, who represented 77.02% of the total 106,691,000 shares, approved the Annual Financial Statements and Consolidated Financial Statements for 2023, the Remuneration Report and the Sustainability Report.

Roche Annual General Meeting 2024

Roche introduces its suite of navify operational excellence solutions, including navify Analytics and navify Monitoring, for use in laboratories and point of care services navify Analytics provides operational insights to lab managers and point of care coordinators to manage workflows more efficiently, reduce costs, and improve productivity Insights from navify Analytics, combined with the real-time insights from navify Monitoring, help laboratories operate more efficiently while maintaining quality and improving test turnaround times for labs ROTKREUZ, Switzerland, March 12, 2024 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) introduces navify Analytics, its suite of cloud-based solutions that provide actionable insights to optimise operational and financial outcomes in laboratories and point of care (POC) settings. navify Analytics for POC will make its debut at the HIMSS 2024 Conference in Orlando, USA, from 11-15 March 2024.

Roche showcases new navify® digital solutions that generate operational insights for faster decision-making in diagnostics at HIMSS¹ 2024

Alnylam Pharmaceuticals

Roche and partner Alnylam said on Tuesday their experimental drug against high blood pressure was shown to work when used in combination with the standard of care in a phase 2 trial.

Roche, Alnylam say blood pressure drug succeeds in mid-stage trial

Basel, 05 March 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and Alnylam announced today that the Phase II KARDIA-2 study [ NCT05103332 ] of zilebesiran, an investigational RNAi therapeutic in development for the treatment of hypertension (high blood pressure) - the leading cause of cardiovascular disease worldwide1 - met its primary endpoint. People with mild to moderate hypertension treated with zilebesiran added to a standard of care hypertension medication experienced a clinically and statistically significant reduction in systolic blood pressure at month three. Zilebesiran added to a standard of care demonstrated an encouraging safety and tolerability profile.

Roche and Alnylam report positive topline results from the Phase II KARDIA-2 study in people with hypertension, demonstrating clinically significant blood pressure reductions with zilebesiran when added to standard of care

Apple

Amazon

ASML Hld

AstraZeneca

Alphabet

GlaxoSmithKline

L'Oreal SA

LVMH Moet Hennessy Louis Vuitton

Microsoft

Netflix

Nestle SA

NVIDIA

Novo Nordisk

Novartis

SAP SE

Sanofi

Tesla

Wall Street loves a good story, as evidenced by the recent focus on a group of stocks called the “GRANOLAS.” These are a group of 11 European stocks that have led Europe's stock markets higher.

‘GRANOLAS' vs. the Magnificent Seven: Which should you dig into now?

Roche is considering selling its lung disease drug Esbriet, Bloomberg News reported on Monday citing people with knowledge of the matter.

Roche explores selling lung disease drug, Bloomberg reports

Roche's financial performance in 2023 showed growth despite the decline in COVID-related sales. The company achieved significant milestones, including US approval for Vabysmo, US review for Xolair, and EU approval for a subcutaneous form of Tecentriq. Roche faces challenges with its pipeline and acquisitions but remains confident in its future growth prospects.

Roche: Strong Long-Term Potential Overshadowed

Basel, 25 February 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today data from Stage 1 of the National Institutes of Health (NIH)-sponsored pivotal Phase III OUtMATCH study evaluating the efficacy and safety of Xolair® (omalizumab) in patients allergic to peanuts and at least two other common foods were published in the New England Journal of Medicine (NEJM) and featured in a late-breaking symposium at the 2024 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting. The study showed treatment with Xolair increased the amount of peanuts, milk, egg, wheat and tree nuts (cashew, hazelnut and walnut) that it took to cause moderate to severe allergic reactions in multi-food allergic people as young as 1 year. Safety findings were consistent with the known safety profile of Xolair across its approved indications and in previous clinical trials.4 The U.S. Food and Drug Administration (FDA) recently approved the expanded use of Xolair in children and adults with IgE-mediated food allergies based on the OUtMATCH data.

New England Journal of Medicine publishes Phase III data showing Xolair significantly reduced allergic reactions across multiple foods in people with food allergies

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today data from Stage 1 of the National Institutes of Health (NIH)-sponsored pivotal Phase III OUtMATCH study evaluating the efficacy and safety of Xolair® (omalizumab) in patients allergic to peanuts and at least two other common foods were published in the New England Journal of Medicine (NEJM) and featured in a late-breaking symposium at the 2024 American Academy of Al.

New England Journal of Medicine Publishes Phase III Data Showing Xolair Significantly Reduced Allergic Reactions Across Multiple Foods in People With Food Allergies

Xolair, a 20-year-old asthma drug sold by Roche and Novartis , significantly reduced allergic reactions in people with multiple severe food allergies in a late-stage trial, researchers reported on Sunday at a medical meeting.

Roche's Xolair reduces reactions to severe food allergies in study

There is a different breed of stocks that investors should be aware of. They are GRANOLAS stocks which can be loosely thought of as the Magnificent Seven, but for European stocks.

Move Over Magnificent 7, Say Hello to the GRANOLAS

Roche (RHHBY) obtains FDA approval for Xolair for the treatment of children and adults with one or more food allergies.

Roche's (RHHBY) Xolair Gets Approval for Food Allergies

Basel, 16 February 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the U.S. Food and Drug Administration (FDA) has approved Xolair® (omalizumab) for the reduction of allergic reactions, including anaphylaxis, that may occur with accidental exposure to one or more foods in adult and paediatric patients aged 1 year and older with IgE-mediated food allergy. People taking Xolair for food allergies should continue to avoid all foods they are allergic to (commonly referred to as “food allergen avoidance”). Xolair should not be used for the emergency treatment of any allergic reactions, including anaphylaxis. Immunoglobulin E (IgE)-mediated food allergies are the most common type and are typically characterised by the rapid onset of symptoms following exposure to certain food allergens.3 Xolair is the first and only FDA-approved medicine to reduce allergic reactions in people with one or more food allergies. Xolair is widely available and can now be prescribed for appropriate patients with IgE-mediated food allergy in the U.S.

FDA approves Xolair as first and only medicine for children and adults with one or more food allergies

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Xolair® (omalizumab) for the reduction of allergic reactions, including anaphylaxis, that may occur with accidental exposure to one or more foods in adult and pediatric patients aged 1 year and older with IgE-mediated food allergy. People taking Xolair for food allergies should continue to avoid all foods.

FDA Approves Xolair as First and Only Medicine for Children and Adults With One or More Food Allergies

PathAI will exclusively work with Roche Tissue Diagnostics (RTD) to develop artificial intelligence (AI) digital pathology algorithms for RTD's companion diagnostics business. The image analysis algorithms will be deployed on Roche's navify Digital Pathology platform, allowing seamless integration into pathology laboratories worldwide.

Roche enters into collaboration agreement with PathAI to expand digital pathology capabilities for companion diagnostics

Some of the biggest European stocks offer a better risk-adjusted return than the Magnificent 7, and that's not their only quality.

Nervous About Nvidia, Tesla and the Magnificent 7? Look at Goldman's GRANOLAS.

For all the attention paid to the highflying tech giants dubbed the Magnificent Seven, there's another grouping that has kept right up with them, and with a lot lower risk.

This grouping of stocks has actually kept up with the Magnificent Seven, and with a lot less risk

Roche is a well-recognized pharmaceutical company with a strong international presence and a market capitalization of CHF 187 billion. Despite recent challenges, Roche's 2024 guidance shows potential for mid-single-digit growth in revenues and EPS, making it an interesting opportunity for long-term investors. We believe that the last few months decline could increase the interest of value investors as the stock is trading at historically low multiple valuation.

Roche: The Recent Sell-Off Created A 30% Upside Potential

Roche is cutting 345 jobs, Swiss website Muula reported, as the drugs company responds to lower profit posted for 2023 and a more cautious outlook for the year ahead.

Roche cutting 345 jobs in product development - media

Roche Holding AG (RHHBY) Q4 2023 Earnings Call Transcript

Roche (RHHBY) misses earnings and sales estimates in 2023 due to a significant decline in COVID-19-test sales. Currency rate fluctuations also impact results.

Roche (RHHBY) 2023 Earnings Miss, COVID-19 Product Sales Down

Roche said on Thursday that 2024 would see a return to sales growth as it is overcoming a slump in demand for its COVID-19 products and the sales decline of a trio of established cancer drugs is abating.

Roche forecasts return to growth in 2024 as it overcomes drop in COVID sales

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today new 72-week data from two global Phase III studies, BALATON and COMINO, evaluating Vabysmo® (faricimab-svoa) in macular edema due to branch and central retinal vein occlusion (BRVO and CRVO). Whereas available RVO treatments are typically given every one to two months, the data showed nearly 60% of people receiving Vabysmo in BALATON and up to 48% of people in COMIN.

New Long-Term Data for Genentech's Vabysmo Show Sustained Retinal Drying and Vision Improvements in Retinal Vein Occlusion (RVO)

Basel, 1 February 2024 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new 72-week data from two global Phase III studies, BALATON and COMINO, evaluating Vabysmo® (faricimab) in macular edema due to branch and central retinal vein occlusion (BRVO and CRVO).1,2 Whereas available RVO treatments are typically given every one to two months, the data showed nearly 60% of people receiving Vabysmo in BALATON and up to 48% of people in COMINO were able to extend their treatment intervals to three or four months apart.1,2,3,4 In addition, patients in the studies maintained vision gains and robust retinal drying achieved in the first 24 weeks of the studies for more than one year. Retinal drying is an important clinical measure as swelling from excess fluid in the back of the eye has been associated with distorted and blurred vision.5 In both studies, Vabysmo was well tolerated and the safety profile was consistent with previous studies.

New long-term data for Roche's Vabysmo show sustained retinal drying and vision improvements in retinal vein occlusion (RVO)

Outlook for 2024 Roche expects an increase in Group sales in the mid single digit range (at constant exchange rates). Core earnings per share are targeted to develop broadly in line with sales growth (at constant exchange rates), excluding the impact from resolution of tax disputes in 2023. Roche expects to further increase its dividend in Swiss francs.

[Ad hoc announcement pursuant to Art. 53 LR] Roche exceeds guidance and achieves sales growth of 1% (CER) for 2023 despite sharp COVID-19 sales decline

News for Roche Holding AG Stock (RHHBY)